PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas

Cancer including melanoma may be “addicted” to double strand break (DSB) repair and targeting this process could sensitize them to the lethal effect of DNA damage. PARP1 exerts an important impact on DSB repair as it binds to both single- and double- strand breaks. PARP1 inhibitors might be highly effective drugs triggering synthetic lethality in patients whose tumors have germline or somatic defects in DNA repair genes. We hypothesized that PARP1-dependent synthetic lethality could be induced in melanoma cells displaying downregulation of DSB repair genes. We observed that PARP1 inhibitor olaparib sensitized melanomas with reduced expression of DNA ligase 4 (LIG4) to an alkylatimg agent dacarbazine (DTIC) treatment in vitro, while normal melanocytes remained intact. PARP1 inhibition caused accumulation of DSBs, which was associated with apoptosis in LIG4 deficient melanoma cells. Our hypothesis that olaparib is synthetic lethal with LIG4 deficiency in melanoma cells was supported by selective anti-tumor effects of olaparib used either alone or in combination with dacarbazine (DTIC) in LIG4 deficient, but not LIG4 proficient cells. In addition, olaparib combined with DTIC inhibited the growth of LIG4 deficient human melanoma xenografts. This work for the first time demonstrates the effectiveness of a combination of PARP1 inhibitor olaparib and alkylating agent DTIC for treating LIG4 deficient melanomas. In addition, analysis of the TCGA and transcriptome microarray databases revealed numerous individual melanoma samples potentially displaying specific defects in DSB repair pathways, which may predispose them to synthetic lethality triggered by PARP1 inhibitor combined with a cytotoxic drug.

[1]  L. Povirk,et al.  Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells , 2016, Radiation Research.

[2]  M. Czyz,et al.  Phenotypic diversity of patient-derived melanoma populations in stem cell medium , 2015, Laboratory Investigation.

[3]  A. Tomkinson,et al.  Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias , 2013, Oncogene.

[4]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[5]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[6]  David J. Chen,et al.  DNA double strand break repair via non-homologous end-joining. , 2013, Translational cancer research.

[7]  A. Roesch.  Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma , 2014, Oncogene.

[8]  T. Pandita,et al.  Rad52 inactivation is synthetically lethal with BRCA2 deficiency , 2010, Proceedings of the National Academy of Sciences.

[9]  E. Newman,et al.  Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma , 2015, Molecular Cancer Research.

[10]  B. Kaina,et al.  Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. , 2009, DNA repair.

[11]  Nicola J. Curtin,et al.  DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.

[12]  Curt I Civin,et al.  Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. , 2013, Blood.

[13]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[14]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[15]  Thomas Helleday,et al.  The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.

[16]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[17]  M. Czyz,et al.  Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations , 2016, Oncotarget.

[18]  Ran Kafri,et al.  Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. , 2012, Molecular cell.

[19]  G. Iliakis,et al.  Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. , 2011, Mutation research.

[20]  B. Kaina,et al.  Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. , 2016, Cancer research.

[21]  G. Shapiro,et al.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. , 2015, Cancer discovery.

[22]  R. Dummer,et al.  Systematic classification of melanoma cells by phenotype‐specific gene expression mapping , 2012, Pigment cell & melanoma research.

[23]  F. Hamdy,et al.  DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair. , 2016, Cancer research.

[24]  T. Skorski,et al.  ATR-Chk1 Axis Protects BCR/ABL Leukemia Cells from the Lethal Effect of DNA Double-Strand Breaks , 2006, Cell cycle.

[25]  S. Boulton,et al.  Playing the end game: DNA double-strand break repair pathway choice. , 2012, Molecular cell.